Obinutuzumab
Primary Mediastinal Large B-Cell Lymphoma
Explore 81 assets in Primary Mediastinal Large B-Cell Lymphoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Acepodia Biotech, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05653271CT.gov ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT04703686CT.gov Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | — | Completed | — | — | — |
NCT04231877CT.gov Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT02393157CT.gov Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Mediastinal Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obinutuzumab (this asset) | Acepodia Biotech, Inc. | P2 | BB · 64 |
| Isocyclophosphamide | David Bond, MD | P4 | BBB |
| Adriamycin | University of Washington | P4 | BBB |
| Etoposide | University of Washington | P4 | BBB |
| (+)-Vincristine | Sun Yat-sen University | P4 | BBB |
| Axicabtagene Ciloleucel | AIDS Malignancy Consortium | P2 | BB |
| Vincristine Sulfate | National Research Center for Hematology, Russia | P3 | BB |
| Cytarabine | Fred Hutchinson Cancer Center | P4 | BB |
| Prednisone | University of Washington | P3 | BB |
+42 more in the Primary Mediastinal Large B-Cell Lymphoma cohort
Other indications for Obinutuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Richter Transformation | — | P2 | BB · 71 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 71 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obinutuzumab in Primary Mediastinal Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obinutuzumab-primary-mediastinal-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →